NCT05223231 2026-02-02
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
Nanjing Leads Biolabs Co.,Ltd
Second Affiliated Hospital, School of Medicine, Zhejiang University
Corbus Pharmaceuticals Inc.
Changhai Hospital